Founder

Indu Pal Kaur (M.Pharm., Ph.D., PDCR)

Among top 2% most cited scientists across the globe as per Elsevier publication by Faculty from Stanford University, USA (2019-20 to 2021-23)

Current Position:

  • Head, Department of Pharmaceutics, UIPS 
  • DPIIT-IPR Chair Professor, Panjab University

Field of Specialization: Pharmaceutics – Formulation technology including Nanomedicine

Correspondence: Professor & Head, Department of Pharmaceutics, University Institute of Pharmaceutical Sciences (UIPS), Panjab University, Sector-14, Chandigarh, India. Pin 160014

Education

2010-2011: Professional Diploma in Clinical ResearchCatalyst Clinical Services Pvt. Ltd, New Delhi, India

1989-1996: Ph. D., (Pharmaceutics), Panjab University, Chandigarh, India

1985-1987: M. Pharmacy, (Pharmaceutics), Panjab University, Chandigarh, India 

1982-1985: B. Pharmacy, Panjab University, Chandigarh, India 

Professional Experience

(Teaching & Research experience of 34 years, at graduate & postgraduate levels)

July 27, 2023 – till date: DPIIT-IPR Chair Professor, Panjab University, Chandigarh, India

June 01, 2020 – May 31, 2023: Chairperson, University Institute of Pharmaceutical Sciences (UIPS), Panjab University, Chandigarh, India

Feb 29, 2012- March 13, 2015: Director, USIC/CIL/SAIF and RSIC, (Central Instrumentation & Analytical Facilities), Panjab University, Chandigarh, India

Feb 01, 2010- till date: Professor, University Institute of Pharmaceutical Sciences (UIPS), Panjab University, Chandigarh, India

Feb 01, 2004-2010: Associate Professor, UIPS, Panjab University, Chandigarh, India

Feb 01, 1999-2004: Senior Assistant Professor, UIPS, Panjab University, Chandigarh, India 

Feb 01, 1995-1999: Assistant Professor, UIPS, Panjab University, Chandigarh, India

1993-1995: Fulltime Lecturer (Temporary appointment), UIPS, Panjab University, Chandigarh, India 

1989-1993: Ad-hoc Lecturer, UIPS, Panjab University, Chandigarh, India

 

Research & Academic Interests

  • Nanoparticulate technology– For improved biopharmaceutical performance of actives including macromolecules, gene and RNA delivery.
  • Ophthalmics– Nanodrop and implant formulations and their testing and evaluation for improved ocular bioavailability and posterior eye delivery.
  • Probiotics– Topical including vaginal, gastroretentive and colon targeted systems with/without natural molecules for better mucosal establishment, viability & effects.
  • Nanofibers using 2D electrospinning- Tissue regeneration, scaffolds, wound dressings, mouth dissolving films, cosmetics
  • Design of Pharmaceutical couture for phytochemicals, antioxidant molecules or natural extracts to upgrade their status from preventives to curatives.
  • Cosmeceuticals– Development using novel technologies, safety and efficiency testing.
  • Toxicity testing– Ames assay; in vivo oral, dermal, and ocular toxicity (OECD guidelines).